TransMedics Group (TMDX), Why Is It Back In The Spotlight?

TransMedics Group (TMDX) is back on investor radar after director David Weill bought 1,336 shares on 11 September 2026, lifting his direct stake to 16,392 shares, worth about US$1.4 million.

Recent trading paints a mixed picture for TransMedics Group. The share price has climbed about 21% over the past 90 days but is still down roughly 32% year to date, while the 3-year total shareholder return of about 64% points to much stronger gains over a longer stretch.

Scan beyond TransMedics Group and identify other medical tech players where insider conviction, balance sheets, and recent price swings intersect with our curated list of list of solid balance sheet and fundamentals (25 results).

After a sharp 90 day rebound and a director buying more stock, TransMedics Group now prompts a simple question: Does the current price still leave enough upside to justify the risks on the table?

Most Popular Narrative: 14% Undervalued

Analysts following TransMedics Group see more upside than the last close of $83.45 suggests, with their fair value sitting at $97.30 based on detailed assumptions about future transplant volumes, margins, and capital needs.

International geographic expansion, especially the planned replication of the U.S. NOP model in Europe (representing 45% of global transplant volumes), could nearly double the company's total addressable market, increasing both top-line revenue potential and the ability to achieve greater operating leverage.

See why 77 investors see TransMedics Group as 14% undervalued.

Result: Fair Value of $97.30 (UNDERVALUED)

Still, the TransMedics Group story can be knocked off course if regulatory scrutiny around organ procurement tightens, or if international expansion hits reimbursement and infrastructure roadblocks.

Find out about the key risks to this TransMedics Group narrative.

Next Steps

Optimistic or cautious about TransMedics Group after this insider move and fair value gap, you now have enough context to act fast and stress test the thesis yourself. To weigh those potential upsides directly against the risks, start with the 4 key rewards.

Looking for more ideas beyond TransMedics Group?

If TransMedics Group has sharpened your thinking, do not stop there. Use fresh watchlist ideas from the Simply Wall Street Screener to keep your research pipeline full.

• Target steadier potential outcomes by scanning a pool of 31 resilient stocks with low risk scores that emphasise resilience when conditions change.
• Spot possible bargains early by reviewing 19 high quality undiscovered gems that combine solid business fundamentals with limited market attention.
• Strengthen your income watchlist by focusing on 7 dividend fortresses that aim to pair higher yields with durable cash generation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com